Searle

Actio Biosciences Appoints Ben Cravatt, Ph.D., to Board of Directors

Retrieved on: 
水曜日, 5月 22, 2024
Research, Genetics, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Scripps Research, American Academy, Faculty, Biology, Royal, Bayer, Education, Heart, Stanford University, B.A, Searle, Therapy, Disease, Physiology, Biochemistry, National academy, Chemical biology, National Academy of Medicine, Searle Scholars Program, Drug discovery, Gene, TSRI, Medicine, Wolf Prize in Chemistry, Royal Society, History, Wolf Prize, Scripps, Pharmaceutical industry

Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced that Ben Cravatt, Ph.D., has joined the company’s board of directors.

Key Points: 
  • Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced that Ben Cravatt, Ph.D., has joined the company’s board of directors.
  • Dr. Cravatt is professor and Norton B. Gilula Chair of Chemical Biology in the Department of Chemistry at The Scripps Research Institute.
  • “By combining genuine expertise across biology, chemistry and genetics, Ben has pioneered an approach to drug discovery and development that sits at the heart of Actio’s mission,” said David Goldstein, Ph.D., co-founder and CEO of Actio.
  • He received a Ph.D. from The Scripps Research Institute (TSRI) in 1996 and joined the faculty at TSRI in 1997.

World-Renowned Ancient DNA Expert, HHMI Investigator, and MacArthur Award Winner Beth Shapiro, Ph.D., Joins Colossal as Chief Science Officer

Retrieved on: 
火曜日, 3月 19, 2024
Environment, Research, Genetics, Environmental Issues, Environmental Health, Biotechnology, Health, Other Science, Science, Genomics, Gene, Executive Committee, National Geographic Explorer, Woolly mammoth, Cell, University, Pennsylvania State University, Television, Life, DNA, Stanford University, CRISPR, Ice, Vertebrate Genomes Project, Hologenomics, Genome, HHMI, Colossal Biosciences, Balliol College, Oxford, Howard Hughes Medical Institute, Ecology and Evolutionary Biology, CSO, Domestication, Natural history, National academy, American Academy, Biology, Searle, George Church, Multimedia, MacArthur Fellows Program, Hunting

Colossal Biosciences, the world’s first de-extinction company, today announced that Beth Shapiro, Ph.D. , internationally renowned evolutionary molecular biologist, leader in paleogenomics, and ancient DNA expert, has joined as Chief Science Officer.

Key Points: 
  • Colossal Biosciences, the world’s first de-extinction company, today announced that Beth Shapiro, Ph.D. , internationally renowned evolutionary molecular biologist, leader in paleogenomics, and ancient DNA expert, has joined as Chief Science Officer.
  • In this role, she will oversee the continued expansion of the company’s de-extinction and conservation science teams.
  • A MacArthur “Genius Grant” Award winner and National Geographic Explorer, Beth Shapiro is a pioneer in the scientific fields of ancient DNA and paleogenomics.
  • “She’s the author of inspiring books 'How to Clone a Mammoth' and 'Life as We Made It,' plus an HHMI and MacArthur Fellow.

HawkEye 360 Names Craig Searle VP of Strategic Finance

Retrieved on: 
木曜日, 10月 19, 2023
Columbia Business School, RF, University, MIT Blackjack Team, Searle, Economics, Growth, HawkEye 360, Business administration, Institute of Management Accountants, Hawk-Eye, Navigation, Master of Business Administration, Communication, Uncertainty, Audit committee, Management, Communications satellite, Advance

HERNDON, Va. , Oct. 19, 2023 /PRNewswire/ -- HawkEye 360 Inc., the world's leading defense technology company for space-based radio frequency (RF) data and analytics, announced today the appointment of Craig Searle as Vice President of Strategic Finance. He is transitioning into this role after serving as a member of HawkEye 360's Board of Directors for the past four years.

Key Points: 
  • HERNDON, Va. , Oct. 19, 2023 /PRNewswire/ -- HawkEye 360 Inc. , the world's leading defense technology company for space-based radio frequency (RF) data and analytics, announced today the appointment of Craig Searle as Vice President of Strategic Finance.
  • "Having worked with the HawkEye 360 leadership team for the past several years I am thrilled to join the company full time," said Searle.
  • "Craig has been an exceptional board member for the past four years and possesses a deep understanding of all facets of our business," said John Serafini, HawkEye 360 Chief Executive Officer.
  • For more information about capabilities of the HawkEye 360 satellite constellation, please visit he360.com .

Bluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice President, head of business development

Retrieved on: 
木曜日, 9月 21, 2023
GMP, Hoffman, Amgen, Senior, Partner, Bayer, MBA, Georgetown University, Chemistry, Adenosine, Patient, Blue jay, Leukemia, Columbia University, Business development, BS, Cancer and Leukemia Group B, Infection, Leukemia & Lymphoma Society, MS, Corporation, Apple tree, Five-prime cap, Liver, NNRTI, Technology transfer, Roche, Business, Gilead Sciences, Amicus, Providence College, CMO, AbbVie, SAN, A2A, Amicus Therapeutics, Therapy, HBV, Catalant, SQZ, Model Business Corporation Act, HIV, Chiron Corporation, Hepatology, Oppenheimer, CMC, NDA, Hepatitis C, IND World's Fair Line, HCV, Management, Pharmaceutical industry, Genentech, ImmunityBio COVID-19 vaccine, Biotechnology, Searle

He will be a member of Bluejay’s Executive team, reporting to Keting Chu, Founder and CEO of Bluejay Therapeutics.

Key Points: 
  • He will be a member of Bluejay’s Executive team, reporting to Keting Chu, Founder and CEO of Bluejay Therapeutics.
  • “I am delighted to welcome Chris to the senior leadership team at Bluejay”, stated Mrs. Chu.
  • “Chris has an outstanding track record in business & corporate development with both public and private biotech and pharma companies.
  • Before joining Bluejay, he served as VP, Business & Corporate development at LEXEO Therapeutics, where he led all business development, strategic transactions and played a significant role in the company’s capital raising activities.

Illinois Biotechnology Innovation Organization Appoints Three Industry Leaders to Board of Directors

Retrieved on: 
火曜日, 10月 18, 2022
Marketing, Allergan, AstraZeneca, Time, Therapy, Baxalta, Clinical professor, Growth, MS, Head, Politics, AbbVie, Colorectal Cancer Alliance, Education, Robert H. Lurie Comprehensive Cancer Center, Champaign County, Illinois, MBA, Research, Mayo Clinic, Piper Sandler Companies, University, Colorectal cancer, Baxter, Industry, Bristol Myers Squibb, Rosalind Franklin University of Medicine and Science, CEO, M&A, International business, Association, Astellas Pharma, Takeda Pharmaceutical Company, United Kingdom, University of Warwick Science Park, Tennant, Notre Dame, Baxter International, Management, Pharmaceutical industry, Merck, Searle, Horizon, Northwestern University, Whalen, Biotechnology

CHICAGO, Oct. 18, 2022 /PRNewswire/ -- The Illinois Biotechnology Innovation Organization (iBIO), the trade association that represents the 88,000 jobs in Illinois' life sciences sector, today announced the addition of three new members to its board of directors: Rahul Jerath, senior director, head of Oncology Business Development & Acquisitions at AbbVie; Phil Tennant, senior vice president and head of Oncology Business Unit at Astellas Pharma, Inc.; and Joe Whalen, senior vice president, Alliances & International Business Development at Horizon Therapeutics."As the Illinois life sciences community experiences unprecedented growth, now is a particularly exciting time to leverage the rich experience and insights of Joe, Rahul and Phil," said John Conrad, iBIO president and CEO. "Each of these new board members brings unique perspectives to our advocacy, community building and education efforts. I look forward to working together as we foster more industry growth in Illinois."

Key Points: 
  • "Each of these new board members brings unique perspectives to our advocacy, community building and education efforts.
  • I look forward to working together as we foster more industry growth in Illinois."
  • With the addition of Whalen, Tennant and Jerath, the iBIO board of directors has 21 members.
  • The Illinois Biotechnology Innovation Organization (iBIO) is a life sciences industry association that represents the 88,000 life sciences employees in Illinois.

Kestra Private Wealth Services Welcomes $130 Million Advisor Trio

Retrieved on: 
水曜日, 7月 27, 2022
Banking, Professional Services, Finance, Goal, RIA, CEO, Culture, Partnership, RIAS, Technology, Broker-dealer, Senior, Searle, Efficiency, Association, LLC, Growth, Financial adviser, 3D printing

Kestra Private Wealth Services, LLC (Kestra PWS), a registered investment adviser subsidiary of Kestra Financial, Inc. (Kestra Financial), today welcomed Robert Searle, Luis Dolan, and Jason Ruel to its platform.

Key Points: 
  • Kestra Private Wealth Services, LLC (Kestra PWS), a registered investment adviser subsidiary of Kestra Financial, Inc. (Kestra Financial), today welcomed Robert Searle, Luis Dolan, and Jason Ruel to its platform.
  • As the industry evolves, we believe Kestra Private Wealth Services robust suite of tools, dedicated management team, and sophisticated technology perfectly positions us to deliver a best-in-class experience for our clients.
  • Kestra Private Wealth Services, LLC (Kestra PWS) is a hybrid registered investment adviser (RIA) supporting fee- and transaction-based independent financial professional teams across the nation.
  • Kestra Financial is the parent company of Kestra IS, member FINRA/SIPC, and also of Kestra Advisory Services, LLC; Kestra PWS; and Kestra Institutional Services, LLC, all federally registered investment advisers.

Asher Bio Appoints Ian T. Clark to Its Board of Directors

Retrieved on: 
月曜日, 2月 14, 2022
Biotechnology, Pharmaceutical, Health, Oncology, United Kingdom, Federal Reserve, Economic Advisory Council, American, Patient, Shire (pharmaceutical company), Cancer, Glassdoor, National Economic Advisory Council, CEO, Board, Chief executive officer, Idiopathic pulmonary fibrosis, Gladstone Institutes, Infection, Autoimmunity, Board of directors, Third Rock Ventures, Novartis, Rheumatoid arthritis, Health care, LinkedIn, Biotechnology, Director, Retirement, Takeda Pharmaceutical Company, Bay, Federal, Commercial Operating System (COS), Marketing, Senior, Monsanto, Association, American City Business Journals, General manager, Biology, Management, Vaccine, Pharmaceutical industry, Genentech, University of Southampton, Sanofi, Searle

Asher Biotherapeutics , a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the appointment of Ian T. Clark to its Board of Directors.

Key Points: 
  • Asher Biotherapeutics , a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the appointment of Ian T. Clark to its Board of Directors.
  • Mr. Clark most recently served as Chief Executive Officer (CEO) and a member of the Board of Directors at Genentech.
  • We are pleased to welcome Ian as a member of our board, said Craig Gibbs, Ph.D., Chief Executive Officer of Asher Bio.
  • I am honored to serve on Asher Bios Board.

Bluejay Therapeutics Announces the Appointment of Nancy Shulman, M.D., as Chief Medical Officer

Retrieved on: 
水曜日, 2月 2, 2022
Therapy, CMC, University, Chicago (franchise), Immunoglobulin G, Amgen, AbbVie, Â, Adenosine, GLOBE, Hotel des Indes (The Hague), Division, NDA, Stanford University, Internal medicine, Five-prime cap, Moses Austin, Hepatitis C, CEO, Apple tree, Roche, Pediatrics, Chemistry, Cancer and Leukemia Group B, Immunology, Hepatitis B, Drug development, Technology transfer, Leukemia & Lymphoma Society, HBsAg, Leadership, Infection, Chiron Corporation, Hepatocyte, Gilead Sciences, Leukemia, SQZ, GMP, NNRTI, Hoffman, HCV, Industry, CHBV, Faculty, Patient, A2A, SAN, Bayer, Partner, HIV, Disease, Catalant, HBV, NIH, Pharmaceutical industry, Management, ImmunityBio, Searle, Blue jay, Biochemistry, Genentech

SAN MATEO, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a private biopharmaceutical company focused on the development of innovative cures for infectious diseases, today announced that Nancy Shulman, M.D., joined Bluejay as chief medical officer, bringing over 20 years of clinical development experience with her to Bluejay Therapeutics.

Key Points: 
  • SAN MATEO, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a private biopharmaceutical company focused on the development of innovative cures for infectious diseases, today announced that Nancy Shulman, M.D., joined Bluejay as chief medical officer, bringing over 20 years of clinical development experience with her to Bluejay Therapeutics.
  • Prior to Bluejay, Dr. Shulman worked at Roche, Genentech, AbbVie, and most recently at Ambys Medicines, where she was the vice president of translational medicine.
  • Prior to joining industry, Nancy was an NIH-funded clinical/translational HIV researcher at Stanford University and was on the faculty in the Division of Infectious Diseases.
  • Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases.

Opthea Appoints Chief Commercial Officer to Lead Commercialization of OPT-302 for Wet AMD

Retrieved on: 
月曜日, 1月 3, 2022
Safety, Chief commercial officer, Private Securities Litigation Reform Act, Novartis, Global, Aerie Pharmaceuticals, Ophthalmology, Retina, Investment, AMD, GLOBE, Database, Company, SEC, CEO, Searle, Diabetic retinopathy, Research, CCO, Glaucoma, Program, DME, Patient, Aerie, Nasdaq, Patent, Drug development, General manager, Technology, ASX, VEGF, Overalls, Bristol Myers Squibb, Global Commercial Credit, Industry, Pharmaceutical industry, Management, Alcon

Optheas Chief Executive Officer, Dr. Megan Baldwin, commented I am delighted to welcome Ms. Robertson to the executive management team to lead both the U.S. and global commercialization activities for OPT-302.

Key Points: 
  • Optheas Chief Executive Officer, Dr. Megan Baldwin, commented I am delighted to welcome Ms. Robertson to the executive management team to lead both the U.S. and global commercialization activities for OPT-302.
  • Ms. Robertsons appointment is timely as we advance our Phase 3 registrational program and commercialization efforts for OPT-302.
  • We look forward to capitalizing on both her deep knowledge of the Company and her experience in overseeing the launch of multiple ophthalmology products.
  • Ms. Judith Robertson is an accomplished life sciences commercial executive with an extensive track record for building, leading and launching several commercial organizations.

Lessonly Adds Debra Searle to Yellowship's Keynote Stage

Retrieved on: 
火曜日, 6月 25, 2019
Debra Searle, Debra, Searle, Raz, Television series

INDIANAPOLIS, June 25, 2019 /PRNewswire-PRWeb/ -- Lessonly , the leader in online training software, announced Debra Searle as a keynote speaker at Yellowship , the company's annual conference dedicated to helping teams Do Better Work.

Key Points: 
  • INDIANAPOLIS, June 25, 2019 /PRNewswire-PRWeb/ -- Lessonly , the leader in online training software, announced Debra Searle as a keynote speaker at Yellowship , the company's annual conference dedicated to helping teams Do Better Work.
  • Unfortunately, he had to be rescued so Debra, a novice rower, continued alone and rowed 3,000 miles from Tenerife to Barbados.
  • It should have taken them six weeks but, to achieve her goal, Debra ended up spending three and a half months at sea.
  • Debra will share the Yellowship keynote stage with Guy Raz, the host of "How I Built This" and "TED Radio Hour."